BMRA Biomerica Inc.

Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16

Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16

IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings.

About Biomerica (NASDAQ: )

Biomerica, Inc. (www..com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica is primarily focused on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

Corporate Contact:

Zack Irani

949-645-2111

Source: Biomerica, Inc.



EN
10/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biomerica Inc.

 PRESS RELEASE

InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code

InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code PLA Code issuance by the American Medical Association CPT editorial panel marks a meaningful step toward attaining health insurance reimbursement and expanded patient access for inFoods® IBSinFoods® IBS provides personalized identification of food triggers to substantially improve IBS-related symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company focused on innovative gastroenterology diagnostics, to...

 PRESS RELEASE

Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Tea...

Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer Brings 20+ years of revenue growth leadership in laboratory testing, clinical diagnostics and global expansionLed successful organizational turnarounds and growth strategies at both Boston Heart Diagnostics and Genova DiagnosticsExtensive track record in commercializing advanced laboratory testing, driving growth and payer strategies IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology so...

 PRESS RELEASE

Biomerica Appoints Eric B. Chin to Board of Directors and Audit Commit...

Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin’s appointment strengthens Biomerica’s corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company that develops, patents, manufactures and mark...

 PRESS RELEASE

Biomerica’s inFoods® IBS Clinical Study Results Published in June Issu...

Biomerica’s inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS.Study results suggest inFoods IBS could be particularly beneficial for IBS-M patients, a population with no current FDA-approved drug treatments. IRVINE, Calif., June 05, 2025 (GLO...

 PRESS RELEASE

Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptom...

Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomesPrecision Medicine: inFoods® IBS identifies specific individual food triggers...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch